Atara Biotherapeutics (ATRA) Assets Average (2014 - 2026)

Atara Biotherapeutics' Assets Average history runs 13 years deep, the most recent figure standing at $20.1 million for Q1 2026.

• Quarterly Assets Average fell 76.49% year-over-year to $20.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.1 million (down 76.49% YoY) and the FY2025 annual result came in at $64.7 million, down 52.9% from the prior year.
• Assets Average was $20.1 million for Q1 2026 at Atara Biotherapeutics, down from $25.2 million in the prior quarter.
• Across five years, Assets Average topped out at $432.7 million in Q1 2022 and bottomed at $20.1 million in Q1 2026.
• A 5-year average of $200.5 million and a median of $165.4 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average decreased 11.28% — and 2025, when it tumbled 79.98%.
• Atara Biotherapeutics' Assets Average stood at $372.4 million in 2022, then plunged by 52.43% to $177.1 million in 2023, then slipped by 28.93% to $125.9 million in 2024, then tumbled by 79.98% to $25.2 million in 2025, then declined by 20.18% to $20.1 million in 2026.
• Business Quant data shows ATRA's Assets Average at $20.1 million in Q1 2026, $25.2 million in Q4 2025, and $33.5 million in Q3 2025.